Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
China Medical System sells prescription medicines in China, mostly through a network of sales reps who visit hospitals and doctors.
China Medical System is a drug seller — not a drug inventor, mostly. It buys or licenses medicines that other companies have already developed, then uses its own large sales force to get those drugs into Chinese hospitals and onto doctors' prescription pads. It also sells some treatments outside China, but the heart of the business is the mainland hospital channel.

The company's specialty is the unglamorous plumbing of Chinese medicine: relationships. It focuses on hospitals and doctors in fields like cardiology, digestive health, dermatology, and ophthalmology, and it pays for armies of sales representatives to visit them. For a foreign or smaller drugmaker that has a good medicine but no way to reach thousands of Chinese hospitals, licensing the drug to China Medical System is the shortcut. For the company, that means it earns money on other people's science. That model has a built-in weak spot. A big chunk of its revenue has long come from a few licensed products, and when one of those loses patent protection or gets hit by China's aggressive drug-price cuts, the business feels it fast. China's centralized procurement program — where the government bulk-buys drugs and squeezes prices hard — is the single biggest threat to the business. There is also political risk: a few years ago Chinese authorities investigated the company over how it paid for a drug license, a reminder that this business runs on government goodwill.
To reduce its dependence on a handful of imported drugs, the company has been building up its own pipeline of newer medicines and buying stakes in biotech firms, including in skin and eye treatments. It has also expanded overseas. The bet is straightforward: own more of what it sells, so price cuts hurt less. Whether that bet pays off is the main question for investors.
Saved answer · last researched 16 Nov 2026